ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Saturday, November 12, 2022

1:00PM-3:00PM: Abstract Number: 0354

Clinical and Economic Characterization of Systemic Lupus Erythematosus Patients by Cumulative Corticosteroid Dose over 1 Year: Real-World Observation of Commercially Insured Adults in the United States

SLE – Treatment Poster I

1:00PM-3:00PM: Abstract Number: 0341

Clinical Applications of Urine SERPINC1/ORM1 in MRL-lpr Lupus Nephritis-Prone Mice

SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis

1:00PM-3:00PM: Abstract Number: 0436

Clinical Characteristics and Outcome of ANCA-Associated Vasculitides Induced by Anti-Thyroid Drugs: A Multicenter Retrospective Cohort Study

Vasculitis – ANCA-Associated Poster I: Epidemiology, Outcomes, and Classification

1:00PM-3:00PM: Abstract Number: 0172

Clinical Characteristics and Outcomes of Inflammatory Myositis Related Interstitial Lung Disease: A 15 Year Retrospective Study

Muscle Biology, Myositis and Myopathies Poster I

1:00PM-3:00PM: Abstract Number: 0439

Clinical Characteristics of Patients with ANCA-Associated Vasculitis with and Without Alpha-1 Antitrypsin Deficiency Alleles

Vasculitis – ANCA-Associated Poster I: Epidemiology, Outcomes, and Classification

1:00PM-3:00PM: Abstract Number: 0162

Clinical Features Associated with the Presence of anti-SSA/Ro60 Antibodies in anti-Jo-1 Antibody-positive Myositis

Muscle Biology, Myositis and Myopathies Poster I

1:00PM-3:00PM: Abstract Number: 0281

Clinical Outcomes of Filgotinib in Patients with RA Aged ≥65 Years: A Post Hoc Subgroup Analysis of Phase 2 and 3 Clinical Trials and Ongoing Long-Term Extensions

RA – Treatment Poster I

1:00PM-3:00PM: Abstract Number: 0085

Closing the Gender Gap in Global Rheumatology Leadership- Are We There Yet?

Healthcare Disparities in Rheumatology Poster

1:00PM-3:00PM: Abstract Number: 0433

Clustering of Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis – Using a Pre-processed Harmonised Dataset

Vasculitis – ANCA-Associated Poster I: Epidemiology, Outcomes, and Classification

1:00PM-3:00PM: Abstract Number: 0048

Combination of Repetitive Inhalant Endotoxin Exposure and Collagen-induced Arthritis Interact in a Testosterone-dependent Manner to Drive Inflammatory Lung Disease Processes and Arthritis Severity in Mice

RA – Animal Models Poster

1:00PM-3:00PM: Abstract Number: 0134

Combination Treatment with Baricitinib and Pulse Steroids in Severe COVID19: A

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

1:00PM-3:00PM: Abstract Number: 0246

Comorbidity Clusters in Patients with Rheumatoid Arthritis Predict Survival Prognosis

RA – Diagnosis, Manifestations, and Outcomes Poster I

1:00PM-3:00PM: Abstract Number: 0367

Comparative Risk of COVID-19 Among Patients with Systemic Lupus Erythematosus According to Immunosuppressant Use

SLE – Treatment Poster I

1:00PM-3:00PM: Abstract Number: 0349

Comparative Risks of Infection with Belimumab versus Oral Immunosuppressants in Patients with Non-Renal Systemic Lupus Erythematosus

SLE – Treatment Poster I

1:00PM-3:00PM: Abstract Number: 0284

Compared Mortality and Cardiovascular Safety of JAK Inhibitors and Tocilizumab in Patients with RA : A Systematic Review and Network Meta-analysis

RA – Treatment Poster I

«Previous Page
1
…
5
6
7
8
9
…
39
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].